Hypertension and Diabetes. Edward Shahady MD Medical Director Diabetes Master Clinician Program Florida Academy of Family Physicians

Similar documents
Management of Hypertension

ADVANCES IN MANAGEMENT OF HYPERTENSION

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

ADVANCES IN MANAGEMENT OF HYPERTENSION

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Hypertension (JNC-8)

Managing Hypertension in 2016

Index. Note: Page numbers of article titles are in boldface type.

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Preventing and Treating High Blood Pressure

Modern Management of Hypertension

Clinical Recommendations: Patients with Periodontitis

Modern Management of Hypertension: Where Do We Draw the Line?

By Prof. Khaled El-Rabat

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

hypertension Head of prevention and control of CVD disease office Ministry of heath

Combination Therapy for Hypertension

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

Hypertension. Most important public health problem in developed countries

Hypertension Pharmacotherapy: A Practical Approach

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

STANDARD treatment algorithm mmHg

Hypertension. Penny Mosley MRPharmS

Management of High Blood Pressure in Adults

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Difficult to Treat Hypertension

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Section 3, Lecture 2

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Hypertension Update Clinical Controversies Regarding Age and Race

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Diabetes in Asian Americans

What in the World is Functional Medicine?

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

HTN talk_l Davis_ /28/2018

Beta 1 Beta blockers A - Propranolol,

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Cedars Sinai Diabetes. Michael A. Weber

Diabetes and Hypertension

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

Update in Hypertension

Pediatric Hypertension. Alisa A. Acosta, MD, MPH Asst. Professor, Renal Section April 5, 2019

Treating Hypertension from

How to approach resistant hypertension. Teh-Li Huo, M.D., Ph.D.

Dr Doris M. W Kinuthia

Getting BP to goal: Virginia L. Hood MB.BS, MPH, FACP

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg

Antihypertensives. Diagnostic category

Updates in primary hyperaldosteronism and the rule

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale

Updates in primary hyperaldosteronism and the rule

ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome and Chronic Kidney Disease

LXIV: DRUGS: 4. RAS BLOCKADE

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Hypertension, also referred to as high blood

Jared Moore, MD, FACP

Update on Current Trends in Hypertension Management

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist

5.2 Key priorities for implementation

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Adult Blood Pressure Clinician Guide June 2018

TREATMENT OF HYPERTENSION

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Dr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Categories of HTN. Overview of Hypertension. Types of Hypertension

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

New and Emerging Therapies for Type 2 DM

Antialdosterone treatment in heart failure

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Risk Factors for Heart Disease

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

Primary Aldosteronism

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

What s all the Fuss?

Byvalson. (nebivolol, valsartan) New Product Slideshow

Transcription:

Hypertension and Diabetes Edward Shahady MD Medical Director Diabetes Master Clinician Program Florida Academy of Family Physicians

Objectives Describe the prevalence of hypertension and hypertension control in diabetes. Describe non medication issues in Hypertension Understand why diabetic patients have more hypertension Develop an approach to hypertension Review treatment options for hypertension

Ong et al Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999 2004. Ann Epidemiol 2008;18:222 229

B/P Awareness, treatment and control 2007 2008 NHANES Awareness Treatment Control 80 % 70% 80 70 60 50 40 30 20 10 0 BP NHANES 2007-2008 50% B/P control better in White vs Black and Hispanic Patients JAMA. 2010;303:2043-2050

BP Control in Patients with Diabetes Presence of hypertension increases the risk of cardiovascular disease (CVD) ~ 2 to 4-fold in T2DM The risk for CVD and renal failure is increased ~ 2 to 4-fold in patients with T2DM who have albuminuria Schrier, R., et al. Kid Internal. 61: 1086-1097, 2002.; Schrier, R., et al. Nat Clin Proc. 3:428-438, 2007.; ADA-Standards of Medical Care in Diabetes 2011. Diabetes Care 33:S11-S61, 2010.

Micro-albuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression 1433 patients treated for 2 years either with an ACEi or ARB, at adequate doses, alone or in combination with other antihypertensive drugs. 16.1%developed new-onset micro-albuminuria, and 1% macro-albuminuria Albuminuria appeared at any level of blood pressure (BP) from below 130/80 mmhg, albeit the highest percentage was seen when SBP was above 160 mmhg. Ruilope et al Hypertension November 2011

F/U DCCT/EDIC NEJM Nov 11 2011 ISSUE

Hypertension Non Medication Issues Cost and cost savings Age-goals? Gender-Race Home vs Office B/P Physical Activity Sodium Intake Use of NSAIDS and Alcohol Adherence-?50% Comorbidities-glucose and lipid levels, CVD, depression, diabetes distress

Why do Patients with Diabetes have more Hypertension and which came first?

Normal Glucose Homeostasis GI tract Ingestion of food Release of gut hormones (incretins) Insulin from β cells uptake of Glucose by muscle and FFA by adipose tissue Pancreas Blood glucose homeostasis Glucagon from α cells Glucose production by liver Kahn CR, Saltiel AR (2005), Joslin s Diabetes Mellitus, 14th ed. Lippincott Williams & Wilkins; pp145-168 Glucose produc on by Kidney glucose and sodium renal reabsorption SGLT2

The Sick Dysfunctional Insulin Resistant Adipocyte Hypertension Agiotensinogen New Drugs for Inflammation TNFα IL-6 Adipsin (Complement D) Adipose tissue Lipoprotein lipase Insulin FFA Resistin Leptin Hepatic Cardiac Steatosis Glucose Intolerance Note the Adiponec n Plasminogen activator inhibitor-1 (PAI-1) Thrombosis Triglycerides HDL Bays H, Mandarino L, DeFronzo RA J Clin Endocrinol Metab 2004;89:463 78

Insulin Resistance and Hypertension Increased insulin levels increase renal sodium and water retention Hyperinsulinemia increases sympathetic activity this impacts B/P regulation Onset of diabetes with insulin resistance delayed up to 10 years but hypertension secondary to Hyperinsulinemia comes early and more predictable. Bloomgarden Z, Obesity, Hypertension, and Insulin Resistance Diabetes Care 2002; 25: 2088-97

B/P Measurement? Where and Accuracy Office? Home? Tele-monitoring?

American Heart Association standards for measuring blood pressure The patient should be seated comfortably with the back supported and the upper arm bared without constrictive clothing. The arm should be supported at heart level, and the bladder of the cuff should encircle at least 80% of the arm circumference. Neither the patient nor the observer should talk during the measurement. Recommendations for Blood Pressure Measurement Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Hypertension 2005;45:142-161

Home Blood Pressure Monitoring

12 year follow up with 10 mm Hg in Syst B/P over baseline LVH regression after one year of Rx with ACE and diuretic Home Blood Pressure Monitoring A Tool for Better Hypertension Control (Hypertension. 2011;57:21 23.)

Treatment What issues do you consider before starting medication?

What are the issues we address when deciding when and how to Rx B/P? Age? Weight Sodium Intake Gender-Race Physical Activity Use of NSAIDS and Alcohol Presence of dyslipidemia LDL, HDL etc

Response to salt more dramatic in some individuals. Overweight Older Metabolic Syndrome Renal Disease Diabetes Insulin Resistance African American Lancet 2009; 373: 829 35 Diabetes Insight Vol 01, Issue 15 Nov 2010

Salt Sensitivity and Insulin Resistance High levels of salt increases sympathetic nervous system activity Insulin resistance and hyperinsulinemia increase salt sensitivity Insulin affects salt transport in proximal renal tubules Obesity affects salt regulation through effect on renal function Nutr Metab Cardiovasc Dis. 2000;5:287-94.

Blood Pressure and Race African Americans and other Black Patients have increased rates of Hypertension. Race has little value in predicting the response to antihypertensive drugs due to the great overlap in drug classes. Most whites and blacks have similar responses to commonly used antihypertensive drugs. Focus on individual rather than on race Sehgal AR. Hypertension. 2004;43:566-572.

Blood Pressure and T2 Diabetes Risk in African Americans and Whites Data from the Atherosclerosis Risk in Communities (ARIC), Coronary Artery Risk Development in Young Adults (CARDIA), and Framingham Heart studies to examine higher blood pressure (BP) as a risk factor for newonset diabetes in middle-aged African Americans and whites. Subjects (N=10,893) were aged 35 54 years 57% were female; 23.4% were African American. At baseline, whites had more favorable BP, adiposity, fasting glucose and insulin profiles, smoking prevalence, and education; African Americans had more favorable lipid levels. After 8.9 years median follow-up, 7.9% of whites developed diabetes vs 14.6% of African Americans. Wei GS, Coady SA, Goff DC Jr, et al. Blood pressure and the risk of developing diabetes in African Americans and Whites. Diabetes Care. 2011;34(4):873-879.

Measures of novel atherosclerosis mediators before and after diet and exercise Mediator Before diet and exercise After diet and exercise MPO (ng/ml) 166.2 132.7 <0.05 Serum CRP (mg/l) 2.39 1.46 <0.01 ICAM-1 (ng/ml) 363.5 291.2 <0.05 sp-selectin (ng/ml) 147.5 135.3 <0.01 MMP-9 (ng/ml) 779.3 625.7 <0.01 Monocyte adhesion 185.3 127.7 <0.001 THP-1/HPF MCA migrated monocytes/hpf 16.5 11.1 <0.01 MPO=myeloperoxidase, an enzyme that induces oxidative stress CRP=C-reactive protein ICAM=intracellular adhesion molecule MMP=matrix-metalloproteinase MCA=monocyte chemotactic activity HPF=high power field Roberts CK et al. J Appl Physiol 2006; available at: http://jap.physiology.org. p

Why worry about B/P?

Risk of Heart Attack with increasing Blood Pressure and hscrp > 3 and <3 hscrp <3 Circulation. 2003;108:2993 2999.) Relationship between blood pressure, C-reactive hscrp >3 protein (CRP), and ifirst cardiovascular events 15 215 women followed prospectively over a median of 8.1 years. P trend 0.0001).

What is your target for B/P In your patients with Diabetes?

Setting BP Targets in T2DM Evidence derived from: UKPDS, a study in newly-diagnosed T2DM ADVANCE trial, a study in established T2DM ACCORD trial, a study in established T2DM Recommended BP Goal: <130/80 mm Hg

What medications do you use for hypertension in diabetes-in what order?

Management of Hypertension (General Principles) Low dose diuretics are effective Usually need multiple drugs Use from different classes of medications Avoid using maximal doses of one agent before adding a second Most drugs cause varying degrees of impotence ACE inhibitors and/or ARBs are preferred first choice

Medications for Hypertension Diuretics (e.g., thiazides, loop diuretics, K-sparing) ACE-inhibitors and ARBs (e.g., lisinopril, losartan) Beta-blockers (e.g., labetalol, metoprolol) Alpha-blockers, central (e.g., clonidine, methyl-dopa) Alpha-blockers, peripheral (e.g., prazosin, terazosin) Calcium-channel blockers (e,g., amlodipine, nifedipine) Vasodilators (e.g., hydralazine, minoxidil) Aldosterone Antagonist (Spironolactone) Aldactone (Amiloride) Midamor

If the patient does not respond to Rx what do you do?

If the patient does not respond to your treatment for hypertension what do you do? Is the patient taking NSAIDS? Is the dietary salt intake excessive? Is the patient taking all their medications as prescribed? Was B/P taken correctly? Would home B/P monitoring be of help? Hyperaldosteronism? Hypokalemia?

Primary Aldosteronism Common cause of resistant Hypertension Prevalence of 3 to 32% of hypertensive patients Only 20% have low K Adrenal Hyperplasia Familial genetic evaluation Adrenal adenoma-30% unilateral and Rx by laparoscopic removal-bilateral 70% Rx with medication Dx by plasma aldosterone/renin ratio >30 ng/100mlseveral requirements like upright for 4 hrs, no diuretics, liberal salt intake etc before test is done Endocrinologist 2004;14:267-76 J Am Coll of Cardiology 2006;48:2293-2300